Market News AIOpen the app

Maxim Group changed its rating for Kairos Pharma from Buy to Hold.

OpinionRead the original at marketscreener.com
Bad for KAPA

Maxim Group cut its Kairos Pharma rating from Buy to Hold. That signals less confidence in the shares, making the news unfavorable for KAPA.

KAPA · Kairos Pharma, Ltd.

AI read · Bad for KAPA

The AI's read

A lower rating means Maxim sees less reason to expect the shares to do well. The report gives no new sales, trial results, or cash figures to balance that warning.

Get alerts for KAPA

Follow Kairos Pharma, Ltd. (KAPA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KAPA
Free on the App Store and Google Play, or on the web.